Home >> Professional Blog

MiMedx EpiFix® Allograft Awarded Coverage
by Health Care Services Corporation (HCSC)

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.

HCSC has approved the reimbursement of EpiFix® for the indications as prescribed by the physician, including wound care, soft tissue replacement or repairs in burns, cardiovascular applications, treatment of ocular surfaces, and the application as a surgical barrier in knee or spine surgeries.

HCSC serves its members through its operating divisions and subsidiaries: Blue Cross and Blue Shield of Illinois, Oklahoma, New Mexico, Texas and Montana, and Dearborn National. With the addition of HCSC, EpiFix is now approved for all of the Blue Cross and Blue Shield members in 20 states.

"Commercial health plans such as HCSC perform a high degree of analysis on the clinical efficacy and cost effectiveness of tissues and products approved for reimbursement. This review focuses on the results of evidenced based clinical studies," commented Bill Taylor, President and COO. "Through our clinical study data presented to the health plans, including clinical data and results from Randomized Control Trials (RCTs) and cross-over clinical studies, we are able to present the evidence necessary to demonstrate that our allografts will benefit their members and should be an essential part of their covered services."

"Often, the commercial carriers parallel the reimbursement approvals from the Centers for Medicare and Medicaid Services. We have successfully secured approval from seven of the eight Medicare Administrative Contractors (MACs). At this point, EpiFix® is approved for reimbursement coverage in 49 of the 50 states. With the extremely fast pace at which the MACs have approved EpiFix®, we expect to see a very rapid rate of reimbursement approvals emanating from the commercial health plans," said Mr. Pete Petit, Chairman and CEO.

MiMedx also reported that its EpiFix® allograft currently has reimbursement approval from 12 state Medicaid Programs.